Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
QCOM$156.03-17.16(-9.91%)Qualcomm Q4: This Dip Is Not The One To Buy Yet7:45:04 AM ETAXP$337.49+4.87(+1.46%)American Express vs. PayPal: Which Financial Stock Is a Better Buy for 2027?7:45:01 AM ETSPCX$132.00-3.92(-2.88%)Stack Capital Group Inc. Reports Q3-2026 Financial Results7:45:00 AM ETCOP$138.55+1.61(+1.18%)BUZZ-ConocoPhillips rises on Q3 profit beat7:40:48 AM ETTGT$165.25+2.20(+1.35%)Target Looks More Attractive Than You'd Think7:31:07 AM ETCOP$138.55+1.61(+1.18%)UPDATE 2-ConocoPhillips beats estimates on higher oil prices, raises dividend7:30:23 AM ETCOP$138.55+1.61(+1.18%)ConocoPhillips Q3 profit beats on higher prices, hikes dividend7:26:13 AM ETMETA$636.80+6.80(+1.08%)UPDATE 2-Meta sells first bonds in euros, raises €9 billion7:25:25 AM ETDTE$137.45-0.06(-0.04%)UPDATE 1-DTE Energy to sell its non-utility business for about $3 billion7:23:30 AM ETAAPL$352.76+3.25(+0.93%)Jim Cramer's Surprise Midterm Winner: Apple, Because Fewer Data Centers Could Mean Cheaper Memory7:19:09 AM ETTSLA$376.71-8.48(-2.20%)Ferrari vs. Tesla: Can the Luce Outsell the Roadster?7:18:00 AM ETMU$754.99-40.47(-5.09%)Could Buying Micron Stock Today Help Set You Up for Life?7:17:00 AM ETMSFT$556.50+0.70(+0.13%)Microsoft Is Executing an Irreproducible Balance-Sheet-Backed Infrastructure Pre-Sale at Scale7:15:58 AM ETAAPL$352.76+3.25(+0.93%)Apple Vs. Tesla: Low CapEx Only Matters if Non-Cyclical Cash Flows Come With It7:15:57 AM ETIREN$20.59-1.11(-5.12%)IREN is Only Fit for a Specific Investor Currently7:15:22 AM ETCOP$138.55+1.61(+1.18%)BRIEF-Conocophillips Q3 Adjusted EPS USD 3.27 Vs. IBES Estimate USD 2.977:13:20 AM ETMU$754.99-40.47(-5.09%)Micron Just Closed Below $800 for the First Time Since July7:12:48 AM ETAAPL$352.76+3.25(+0.93%)Amazon, Apple, FTAI Aviation And A Basic Material Stock: CNBC's ‘Final Trades'7:12:08 AM ETCOP$138.55+1.61(+1.18%)ConocoPhillips beats profit estimates, boosts quarterly dividend7:11:13 AM ETCRWD$234.00-7.00(-2.90%)Too Late to Buy CrowdStrike Stock? Here's the 1 Thing to Watch.7:10:00 AM ETGOOG$289.89+2.59(+0.90%)These 6 Stocks Make Up a Big Share of the S&P 5007:09:00 AM ETCOP$138.55+1.61(+1.18%)UPDATE 1-ConocoPhillips beats profit estimates, boosts quarterly dividend7:07:07 AM ETLLY$1,434.00+15.86(+1.12%)Iconic California Brand, French Florist, Celebrates Grand Opening of First Indiana Location7:07:00 AM ETCVS$80.86+0.87(+1.09%)ProjectLeo, the First Private AI Health Platform to Declare Independence From Big Tech7:04:00 AM ET

COLL · NASDAQ

Collegium Pharmaceutical, Inc.

$23.67 0.00 (0.00%)

Company overview

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company that develops and commercializes medicines for pain management. Its product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Market cap
$771M
Employees
357
Headquarters
Stoughton, MA
Website
collegiumpharma.com
CEO
Vikram Karnani
Listed
May 7, 2015
P/E
9.99
Dividend yield
0.00%

Company financials

Revenue
$796M
Gross profit
$483M
Operating income
$190M
EBITDA
$607M
Net income
$74.9M
EPS
$2.37
Total assets
$1.7B
Total debt
$808M
Gross margin
60.68%
Net margin
9.41%
Earnings yield
10.01%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

20.6725.8230.9736.1141.26
COLL 1D NASDAQ O24.11H24.48L23.42C23.67-0.06 (-0.25%)Vol618.19K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
COLLCollegium Pharmaceutical, Inc. Press release Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance GlobeNewswire
COLLCollegium Pharmaceutical, Inc. Stock news Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance GlobeNewswire
COLLCollegium Pharmaceutical, Inc. Stock news COLL or SDZNY: Which Is the Better Value Stock Right Now? Zacks Investment Research
COLLCollegium Pharmaceutical, Inc. Stock news Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to Decline Zacks Investment Research
COLLCollegium Pharmaceutical, Inc. Press release Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts GlobeNewswire
COLLCollegium Pharmaceutical, Inc. Press release Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026 GlobeNewswire
COLLCollegium Pharmaceutical, Inc. Press release Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses GlobeNewswire
COLLCollegium Pharmaceutical, Inc. Stock news COLL vs. DSNKY: Which Stock Is the Better Value Option? Zacks Investment Research
COLLCollegium Pharmaceutical, Inc. Stock news Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut Seeking Alpha
COLLCollegium Pharmaceutical, Inc. Stock news Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect? Zacks Investment Research
COLLCollegium Pharmaceutical, Inc. Stock news New Strong Sell Stocks for October 7th Zacks Investment Research
COLLCollegium Pharmaceutical, Inc. Press release Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life GlobeNewswire
COLLCollegium Pharmaceutical, Inc. Stock news Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
COLLCollegium Pharmaceutical, Inc. Press release Collegium to Participate in Upcoming Investor Conferences GlobeNewswire
COLLCollegium Pharmaceutical, Inc. Stock news 44,493 Shares in Collegium Pharmaceutical, Inc. $COLL Purchased by Freestone Grove Partners LP Defense World
COLLCollegium Pharmaceutical, Inc. Stock news BlackRock Inc. Takes $196.97 Million Position in Collegium Pharmaceutical, Inc. $COLL Defense World
COLLCollegium Pharmaceutical, Inc. Stock news A Look at Collegium Pharmaceutical Inc (COLL) After 3.9% Decline -- GF Value $47.17 vs Price $26.39 GuruFocus
COLLCollegium Pharmaceutical, Inc. Press release Collegium Announces $50 Million Accelerated Share Repurchase Program GlobeNewswire
COLLCollegium Pharmaceutical, Inc. Stock news Avenue Therapeutics (NASDAQ:ATXI) and Collegium Pharmaceutical (NASDAQ:COLL) Head-To-Head Survey Defense World
COLLCollegium Pharmaceutical, Inc. Stock news Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript Seeking Alpha
See more
FAQ

Questions about Collegium Pharmaceutical, Inc.

What does Collegium Pharmaceutical, Inc. do?
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company that develops and commercializes medicines for pain management. Its product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
What is COLL's market cap?
Collegium Pharmaceutical, Inc. (COLL) is a listed stock with a live quote. The latest market cap on this page is $771M.
Where is Collegium Pharmaceutical, Inc. headquartered?
Collegium Pharmaceutical, Inc. is headquartered in Stoughton, MA.
How do I get COLL news from the API?
Call GET /v1/news?tickers=COLL. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does COLL news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for COLL, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the COLL price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs